54 results on '"Corley, Douglas A."'
Search Results
2. Table S1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
3. Table S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
4. Table S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
5. Data from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
6. Data from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
7. Supplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
8. Supplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
9. Data from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
10. Supplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
11. Table S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
12. Table S1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
13. Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
14. Table S1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
15. Supplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
16. Table S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
17. Supplementary Figure 2 from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
18. Data from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
19. Supplementary Figure 1 from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
20. Supplementary Data from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
21. Data from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
22. Supplementary Figure 3 from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
23. Supplementary Data from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
24. Supplementary Figure 3 from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
25. Supplementary Figure 2 from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
26. Supplementary Figure 1 from Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
27. Supplementary Tables S1-S2 from Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems
28. Supplementary Figure legends from A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus
29. Supplementary Tables S1-S4 from Metformin Use and Risk of Colorectal Adenoma after Polypectomy in Patients with Type 2 Diabetes Mellitus
30. Supplementary figure 1 from A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus
31. Data from Pleiotropic Analysis of Cancer Risk Loci on Esophageal Adenocarcinoma Risk
32. Supplementary Tables S1-S4 from Metformin Use and Risk of Colorectal Adenoma after Polypectomy in Patients with Type 2 Diabetes Mellitus
33. Supplementary Tables S1-S2 from Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems
34. Supplementary figure 1 from A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus
35. Data from A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus
36. Validation of a Genetic-Enhanced Risk Prediction Model for Colorectal Cancer in a Large Community-Based Cohort
37. Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old
38. Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval
39. eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
40. Abstract 1446: Genetic risk factors for the development of multiple primary cancers
41. Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda
42. Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
43. Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems
44. Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study
45. Abstract B25: Black-white differences in colorectal cancer screening and incidence over time by age and sex
46. Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems
47. Metformin Use and Risk of Colorectal Adenoma after Polypectomy in Patients with Type 2 Diabetes Mellitus
48. Pleiotropic Analysis of Cancer Risk Loci on Esophageal Adenocarcinoma Risk
49. A Newly Identified Susceptibility Locus nearFOXP1Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus
50. The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.